MedTrace Logo

Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients

NCT05993390 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-06-24

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effect of use of reversal agents for neuromuscular blockade in critically ill patients on time for neurological assessment after endotracheal intubation

The main questions it aims to answer are:

* The use of reversal agents for neuromuscular blockade after endotracheal intubation may reduce the time for neurological assessment.
* The types of reversal agents for neuromuscular blockade may affect the time for neurological assessment.

Participants will receive different reversal agents or no medications based on the assigned groups. Thirty minutes after intubation using rocuronium, medication is administered, and the time of initial confirmation of eye opening and movement is recorded.

Researchers will compare 3 groups (sugammadex, neostigmine and control(no medication) to see the difference of time for neurological assessment after endotracheal intubation.

Conditions

  • Neuromuscular Blockade
  • Critical Illness
  • Neurologic Findings

Interventions

DRUG

Sugammadex

Intravenous administration of sugammadex 2mg/kg.

DRUG

Neostigmine

Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Ho Geol Ryu, M.D., Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2025-08-14
Completion
2025-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05993390 on ClinicalTrials.gov